Medincell Appoints Three New Board Members

Medincell has announced the appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors following a general assembly on September 11, 2025. Dr. Mates, co-founder of Intra-Cellular Therapies, brings notable biopharma leadership with her pivotal role in developing the drug CAPLYTA®. Dr. Kunsch, a former managing director at AbbVie Ventures, is recognized for his extensive venture capital and biotech experience. Dr. Touchon, with over 40 years of expertise, has played key roles in biopharmaceutical companies such as Novartis Oncology.

Philippe Guy, Chairman of Medincell’s Board, highlighted the wealth of experience and strategic vision these new members bring. This move is part of Medincell's ongoing efforts to reinforce its leadership and expand its impact in the biopharmaceutical sector.